spacer
home > white papers > Pharmacovigilance and Risk Management Information in Centralised Applications in the EU - United BioSource Corporation (UBC)
WHITE PAPERS
logo_United_Bio2.JPG

United BioSource Corporation (UBC)

phone +44 (0) 208.834.0100
email contact@ubc.com
web http://www.ubc.com/europe
email 26-28 Hammersmith Grove London, W6 7HA, United Kingdom

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
Pharmacovigilance and Risk Management Information in Centralised Applications in the EU
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection Established platform technology to reliably scale target molecules Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>


White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>


Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement